For frail elderly patients, it's crucial to discern if poor performance status stems from disease or comorbidities. A practical approach is to initiate treatment with biologic agents alone. If the patient's status improves, it confirms the cancer is the cause, justifying the subsequent, careful addition of cytotoxic chemotherapy.

Clinicians ordering "NGS for lung" often misunderstand that Next-Generation Sequencing alone does not cover all actionable biomarkers, such as PD-L1 or HER2. This requires pathologists to interpret the clinician's intent and order a more comprehensive and appropriate test panel.

Contrary to fears based on T-cell engagers in hematologic cancers, CRS with the DLL3 bispecific tarlatamab in SCLC is typically mild and easily managed. An expert describes it as "scary until you're treating patients and then you find that it's pretty anticlimactic," reassuring community oncologists about the therapy's safety profile.

Despite mutation testing being a critical first step for effective treatment planning in gastrointestinal stromal tumors (GIST), a significant number of patients in the United States still do not receive this essential diagnostic. This highlights a major gap between established best practices and real-world clinical application.

For acutely ill patients with strong clinical suspicion of SCLC, delaying treatment for biopsy confirmation can mean losing the window for effective intervention. Initiating chemotherapy in the hospital based on clinical presentation is a critical, potentially life-saving measure.

Despite its approval, the bispecific T-cell engager tarlatamab sees slower community adoption than prior SCLC drugs. The barrier is the logistical need for inpatient monitoring and specialized supportive care for potential cytokine release syndrome during the first two doses, a new challenge for community practices that suggests a university collaboration model.

The most significant, lasting effects of treatment toxicities on quality of life often become most apparent *after* therapy has concluded. Clinical trials that stop collecting data shortly after treatment completion miss this crucial long-term impact, underestimating the true burden of side effects.

Real-world data shows higher rates of cytokine release syndrome (CRS) with tarlatumab than trials reported, especially in sicker patients. Despite this, the drug's risk-benefit profile is often better than chemotherapy for poor-performance patients, sometimes leading to durable, life-changing outcomes where no other options exist.

The necessary delays for screening, eligibility, and logistical setup for clinical trials and novel agents like tarlatamab can take weeks. This makes them unsuitable for patients with rapid, aggressive disease progression, forcing clinicians to rely on older, faster-acting cytotoxic therapies instead.